A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 >=50%

INTERVENTION: Intervention name : REGN2810/ipi: REGN2810 plus ipilimumab INN of the intervention : Cemiplimab Dosage And administration of the intervention : IV infusion Intervention name : REGN2810/chemo/ipi: REGN2810 plus chemotherapy plus Ipilimumab INN of the intervention : Cemiplimab Dosage And administration of the intervention : IV infusion Control intervention name : Pembrolizumab INN of the control intervention : Pembrolizumab Dosage And administration of the control intervention : IV infusion CONDITION: Non‐small Cell Lung Cancer PRIMARY OUTCOME: Please refer to the URL: https://clinicaltrials.gov/ SECONDARY OUTCOME: Please refer to the URL: https://clinicaltrials.gov/ INCLUSION CRITERIA: Please refer to the URL: https://clinicaltrials.gov/